evt_d1f0f0e6-d5fc-5c2e-850c-936715c4a2cbcand_c910827d-042b-5b61-8f68-c1cc163d5073
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
biliary tract cancer
evd_050f65ec-c12b-5b4e-8b99-dfaa23a28f78, evd_0827a6e8-99c0-5d34-b5be-3dac1c22b43f, evd_744b88f2-d38f-57f0-a83c-95b7fbeaf58d, evd_9c7fbe25-e9c1-5172-922a-584ce6d94c2e, evd_a29044bb-d029-592d-b7e9-4b9849e0d4b6, evd_b7ebdd81-2763-5f65-84cd-156e29e1da38, evd_d252e502-9054-5552-a75a-5c2e14b29299fact_21252983-fb4b-5158-a1f2-d8fc81178e38, fact_bd926c0a-e740-5903-98d9-4e2687f6ae62rel_13a3c330-2d9e-57ab-baf5-1019c101123d, rel_6be60f21-9a0e-5580-83e9-4b4e742de37c, rel_935b11eb-96a4-5cc9-95cb-aac65ff4bdc0, rel_9e92a79b-2376-5219-94e5-4ed66103e723